

This Page Is Inserted by IFW Operations  
and is not a part of the Official Record

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):


- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning documents *will not* correct images,  
please do not report the images to the  
Image Problem Mailbox.**

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>6</sup>:</b> <b>B65D 77/04, 81/26, A61K 9/20</b>	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 95/34488</b> <b>(43) International Publication Date:</b> 21 December 1995 (21.12.95)
<b>(21) International Application Number:</b> PCT/EP95/02201 <b>(22) International Filing Date:</b> 6 June 1995 (06.06.95)  <b>(30) Priority Data:</b> 9411626.6                      10 June 1994 (10.06.94)                      GB  <b>(71) Applicant (for all designated States except US):</b> SMITHKLINE BEECHAM PLC [GB/GB]; New Horizons Court, Brentford, Middlesex TW8 9EP (GB).  <b>(72) Inventors; and</b> <b>(75) Inventors/Applicants (for US only):</b> TASKIS, Charles, Bernard [GB/GB]; SmithKline Beecham Pharmaceuticals, Clarendon Road, Worthing, West Sussex BN14 8QH (GB). WHATMORE, Paul, John [GB/GB]; SmithKline Beecham Pharmaceuticals, Clarendon Road, Worthing, West Sussex BN14 8QH (GB).  <b>(74) Agent:</b> WALKER, Ralph, Francis; SmithKline Beecham, Corporate Intellectual Property, SB House, Great West Road, Brentford, Middlesex TW8 9BD (GB).		<b>(81) Designated States:</b> JP, US, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).  <b>Published</b> <i>With international search report.</i>

**(54) Title:** PACKAGE**(57) Abstract**

A package comprising a vial (1) provided with a puncturable seal (2), or a syringe or syringe barrel, being permeable to water vapour but impermeable to liquid water, enclosed within an outer container which is less permeable to water vapour, the intermediate space between the inner and outer containers containing a desiccant (10).

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

### Package.

This invention relates to packages, particularly to packages for moisture sensitive pharmaceutical substances.

5 It is normal practice with moisture sensitive pharmaceutical materials intended for parenteral use to package such materials in a glass vial with a rubber stopper to minimise moisture ingress and maintain product stability. Plastics material vials are sometimes required for a product where the high pH of the reconstituted solution may attack glass, but in general they are to be avoided  
10 because even the best are permeable to water vapour to some extent, and result in a shorter shelf life. Although careful control of the manufacturing and processing conditions may reduce the product moisture content to acceptable levels, there are times when this will not be sufficient, and some form of desiccation would be required. While this is fairly straightforward for oral dosage forms by the inclusion  
15 of desiccants in the pack, etc. the demands for sterility in a parenteral product mean that this approach cannot be used.

An example of a moisture sensitive pharmaceutical substance is a pharmaceutically acceptable derivative of the  $\beta$ -lactamase inhibitor clavulanic acid, such as potassium clavulanate. Potassium clavulanate is both hygroscopic and  
20 readily hydrolysed by water, so for handling and long term storage of potassium clavulanate it is necessary for the immediate environment to be kept dry, e.g. 30% Relative Humidity ("RH") or less, preferably 10% RH or less.

Potassium clavulanate is a  $\beta$ -lactamase inhibitor, and is often provided in a formulation in combination with a partner  $\beta$ -lactam antibiotic. A partner which is  
25 often used in injectable formulations is amoxycillin in the form of sodium amoxycillin. Sodium amoxycillin is often used in such formulations in the form of spray-dried sodium amoxycillin, which is a powerful desiccant, and when contained together with potassium clavulanate in a sealed vial such forms of sodium amoxycillin can exert a dehydrating effect which helps to preserve the potassium  
30 clavulanate. Other forms of sodium amoxycillin, such as the anhydrous crystalline form disclosed in EP 0131147 are less desiccating, and although it would be desirable to use such forms in formulations together with potassium clavulanate because of the inherent greater purity of the crystalline form, the problem arises that these forms can be insufficiently desiccating to protect the potassium clavulanate.

35 Packaging systems are known which can desiccate tablets and capsules for swallowing by a patient. For example FR 2660634A discloses a blister pack for tablets in which two blisters are arranged side by side with an interconnecting channel. One of the blisters contains the tablet and the other a desiccant material to desiccate the tablet. EP 0466068A discloses a similar arrangement in which a

capsule is desiccated.

It is an object of this invention to provide a desiccating package which *inter alia* is suitable for use with moisture sensitive pharmaceutical substances and allows sterile dissolution for parenteral administration without the problem of  
5 contamination by desiccant. Other objects and advantages of the invention will be apparent from the following description.

This invention provides a package which comprises an inner container suitable for containment of a pharmaceutical formulation, the inner container being enclosed within an outer container which is substantially less permeable to water  
10 vapour than the inner container, the intermediate space between the inner and outer containers containing a desiccant, characterised in that the said inner container is a vial provided with a puncturable seal, or a syringe or syringe barrel, suitable for use for transdermal injection of a formulation, and being permeable to water vapour but impermeable to liquid water.

15 In the package of the invention, moisture is gradually extracted from the inner container by the action of the desiccant. The water vapour-substantially impermeable outer container prevents ingress of water vapour from outside the package, and the intermediate space moreover acts as a desiccating barrier preventing any water vapour from passing from the exterior of the outer container  
20 of the package into the inner container.

The inner container may be a vial provided with a puncturable seal and or a syringe, or syringe barrel, suitable for use for transdermal injection of a formulation, and may be of generally similar overall construction to conventional known vials or syringes. However whereas in the case of conventional vials,  
25 syringes and syringe barrels materials are generally selected for the walls, stopper, plunger etc. which are highly impermeable to atmospheric water vapour, such as glass and specialised plastics and rubbers, in the present invention at least some such parts of the vial are made of materials which are water vapour-permeable. This enables the use of materials which although they are pharmaceutically  
30 acceptable in other respects and may be otherwise of excellent quality, are normally considered too water vapour-permeable for the containment of moisture-sensitive pharmaceutical products in a conventional vial or syringe where the vial or syringe is exposed to the ambient air.

The inner container is suitably a vial made from pharmaceutically acceptable  
35 water vapour-permeable plastics materials, having a puncturable rubber closure.

By the term "pharmaceutically acceptable" is included plastics materials which are known and acceptable for the containment of pharmaceutical substances, particularly substances for parenteral administration, by virtue of the relative inertness or impermeability of the material thereto. The term also includes plastics

materials which would be acceptable for the containment of pharmaceutical substances except that they are normally considered too water vapour permeable for such use in the absence of an outer container.

Many such plastics materials are known, and examples of these include  
5 acrylics, cellulose, nylons, polyethylene terephthalate, polyethylene, polypropylene, polystyrene and polyvinyls. Preferable other properties of the plastics material used are strength, visual clarity (although coloured or opaque plastic materials may be desirable for use with some light sensitive pharmaceutical substances), and the possibility of sterilisation for example by autoclaving or dry  
10 heat.

Additionally or alternatively the water vapour-permeability of the inner container may be via a water vapour permeable closure for an opening of the container. For example the closure may be a water vapour-permeable puncturable elastomeric seal for the mouth opening of a vial of the type mentioned above for a  
15 formulation for parenteral administration. Alternatively if the inner container is a syringe or syringe barrel the water vapour-permeability of an inner container in this form may be via a water vapour permeable closure for the nozzle or via a water vapour permeable elastomeric plunger for the syringe barrel. Known seals and plungers may be sufficiently water vapour permeable, or they may be specially  
20 made of such a water vapour permeable material such as a natural or synthetic rubber or other elastomer. Suitable elastomeric materials include natural rubbers, synthetic polyisoprene, butyl, halobutyl, nitrile, neoprene, silicone rubbers etc.

The use of such a water vapour permeable closure for an opening of the container may enable the walls of the inner container to be made of a  
25 pharmaceutically acceptable glass, e.g. borosilicate or soda-lime glass, a material which is frequently used for pharmaceutical vials, and which has the advantages of ease of sterilisation and optical clarity (although coloured or opaque glasses may be desirable for use with some light sensitive pharmaceutical substances), though being impermeable to water vapour.

30 The invention in this case takes advantage of a property of plastics material vials that would normally preclude their use for moisture sensitive products, i.e. their permeability, to provide long-term desiccation and stability enhancement.

Similarly, the glass vials are normally sealed with a moisture impermeable elastomer stopper, but a permeable disc seal would enable moisture to be removed  
35 from the vial contents by an external desiccant, without compromising the sterility of the product.

The use of 'standard' plastics material vials means that normal production processes and equipment can be used.

The relative permeability to water vapour of the inner container will depend

*inter alia* upon the nature, surface area and thickness of the walls of the container and of the closure. A suitable thickness for the material of which the inner container is made may be determined by relatively straightforward experimentation for any intended contents. For example the extent of degradation of moisture sensitive contents within the inner container of a package of the invention can be measured, and the parameters of the package, e.g. materials, wall thickness etc. can be adjusted accordingly. It should be noted that the inner container is likely to benefit from the protection provided by the outer container, allowing a relatively thin inner walled inner container to be used.

10 The outer container may be made of any known packaging material which is substantially less permeable to water vapour than the inner container. The outer container is preferably completely impermeable to water vapour. Suitable packaging materials include metals, particularly in the form of thin foils such as aluminium and its alloys, or impermeable plastics materials, or plastics materials/metals laminates. The outer container may for example be in the form of a blister pack, i.e. a blister cavity formed in a first sheet of packaging material, and closed by a second sheet of packaging material across the open face of the cavity, with the inner container within the cavity. The first sheet may be deferrable and the second sheet may be easily torn, so that the vial can be forced through the second sheet by pressure on the blister.

20 Alternatively the outer container may be in the form of a tray or box, closed by a lid or in some other appropriate fashion, both the tray or box and the lid being made of the packaging material, with a substantially water vapour-impermeable seal formed between the lid and the box or tray. Alternatively the outer container may be in the form of a metal foil or foil/plastics material laminate envelope. Alternatively the outer container may be in the form of a container closed by a closure such as a screw cap or other form of conventional closure. Other forms of outer container will be apparent to those skilled in the art.

25 The nature of the outer container wall, and the disposition of the inner container within the outer container may be such that if the inner container is a vial with a puncturable seal for insertion of a hypodermic needle as described above, a hypodermic needle may be inserted through both the wall of the outer container, e.g. at a designated puncturable region therein, and through the seal, avoiding the need to remove the inner container from the outer container.

30 Whatever the form of the outer container, it is preferred that the shape of the outer container conforms closely to the shape of the inner container so that the intermediate space between the inner and outer containers is of relatively small volume, but sufficient to allow free circulation of air around the inner container and into contact with the desiccant material.

The nature and quantity of desiccant material used in the intermediate space between the inner and outer containers of the invention will vary with the nature of the walls and or the closure of the inner container, the nature of the contents of the inner container, and the nature of the outer container. The nature and quantity of desiccant material may easily be determined by straightforward experimentation, as described above, or calculation, with the aim of maintaining the RH within the inner container at a level at which a moisture sensitive material, such as a moisture sensitive pharmaceutical substance, is protected from hydrolytic degradation to the extent that long term storage with an acceptably small level of degradation can be achieved.

In the case of potassium clavulanate and its mixtures with amoxycillin, e.g. crystalline anhydrous sodium amoxycillin, molecular sieve is a suitable desiccant. Suitably the desiccant material may be compacted into a pellet, or contained in a permeable walled sachet, capsule or other container so that the desiccant remains in one place within the intermediate space. Methods of forming such compacts comprising desiccant materials are known, for example by compression, sintering, binders etc. Suitably the desiccant material may be retained in the intermediate space by the formation of a suitable holder or cavity in the outer container wall to hold the desiccant, or the provision of a connected compartment as in EP 0466068A. Suitably such a holder or cavity may hold the desiccant in a position remote from the puncturable seal of a vial of injectable formulation to avoid any risk of contamination of the contents of the vial by the desiccant in the intermediate space

The container of the invention is particularly suitable for the containment of moisture-sensitive pharmaceutical substances such as a formulation of potassium clavulanate and sodium amoxycillin, particularly anhydrous crystalline sodium amoxycillin e.g. as disclosed in EP 0131147.

Moisture ingress through a typical outer container wall material such as an aluminium foil / plastics material laminate overwrap is typically 0.04 mg/day at 30°C / 100% RH, i.e. 14.6 mg/year. Therefore for a three year shelf life a suitable moisture capacity for the desiccant to absorb this quantity of moisture is 44 mg. Typical batches of 700 mg of a mixture of potassium clavulanate and crystalline sodium amoxycillin pick up ca. 0.3% of free moisture if exposed at 25°C / 25% RH i.e. 2.1 mg of water. Molecular sieve has a capacity of ca. 10% water capacity, and 44 + 2.1 mg of water can therefore be absorbed by ca. 500 mg of molecular sieve.

The water vapour transmission rate of a typical 20ml polyethylene vial has been measured at 0.4 mg / day at 25°C / 100% RH. Thus for an initial value of 25% RH inside the vial (e.g. resulting from filling the vial under such RH conditions) and effectively 0% RH inside the outer container, the initial drying rate



will be 0.1mg /day, dropping as the vial contents dry out and the differential water vapour pressure across the vial decreases. It can be calculated that the vial contents would reach 10% RH within 19 days at 25°C .

5 The contents of the inner container may be loaded into the inner container and the inner container then sealed, in an entirely conventional operation, suitably under dry sterile conditions, and the sealed inner container and desiccant material may then be sealed into the outer container, again in a generally conventional manner. Alternative methods of forming and filling the inner container may be used. For example a blow-fill-seal process may be used to blow a vial from hot  
10 molten plastics material, then fill it and seal it, in a continuous operation, the temperature of the hot melted plastics material ensuring sterility.

The invention further provides a package as described above, containing a mixture which comprises potassium clavulanate and sodium amoxycillin.

15 The invention also provides a method of storage of a moisture-sensitive pharmaceutical substance, particularly a pharmaceutical formulation for parenteral administration, comprising the containment of the substance in the inner container of a package of the invention.

The invention will now be described by way of example only with reference to the accompanying drawings, which are intended to be illustrative only of the  
20 invention, and not limiting.

Fig. 1 shows in a part cut away view a package of the invention in the form of a blister pack.

Fig. 2 shows a cross section through the package of Fig. 1 about the line A-A of Fig. 1.

25 Referring to Figs. 1 and 2 a package comprises an inner container in the form of a vial of conventional shape and of about 35 ml capacity (1) made of a plastics material which is permeable to water vapour but impermeable to atmospheric water vapour. The vial (1) is closed by a rubber seal (2) of generally known type having a thinned puncturable region (3) at its centre. The seal (3) is  
30 held in place by a small crimped metal retaining ring (4). The vial (1) contains a moisture sensitive pharmaceutical formulation (5) which can be made up with water for parenteral administration.

A suitable pharmaceutical formulation (5) comprises a coformulation of 500 mg of sodium amoxycillin, e.g. the crystalline anhydrous sodium amoxycillin  
35 disclosed in EP 0131147 A, and 100 mg of potassium clavulanate.

The vial (1-4) is located within a blister pack comprising a sheet of deformable aluminium alloy foil/plastics material laminate (6) in which are formed blister cavities (7), closed by a thin backing sheet of aluminium alloy foil (8), sealed to the sheet (6) by means of an adhesive (not shown). The sheet (6) and the foil (8),

and their sealing together are impermeable to water vapour.

The shape of the outer container (6,7,8) corresponds closely to the shape of the vial (1) so that the intermediate space (9) between the two is of relatively low volume whilst allowing free circulation of air around the vial (1).

5        Within the intermediate space (9) is a pellet of compacted desiccant material (10), being a molecular sieve. The pellet (10) is located in position within the blister (7) at a position remote from the seal (2) of the vial (1).

10       Further blister cavities (7A) are formed in adjacent positions in the sheet (6), and the region of the sheet (6) which includes them may be torn off for use at the perforated line (11) which delineates this region.

15       In use, the desiccant material (10) desiccates the intermediate space (9), and gradually removes water vapour from the interior of the vial (1) through its water vapour-permeable walls, so as to desiccate the interior of the vial and reduce or prevent hydrolytic degradation of the contents (5). The desiccated intermediate space (9) also serves as a desiccating barrier in case any water vapour should penetrate the outer container (6,7,8).

20       In use, the blister (7) may be deformed by pressure and the vial (1) thereby forced out through foil (8). The vial may then be used in the usual manner by insertion of a hypodermic needle (not shown) through the thinned region (3) and introduction of water or other suitable aqueous medium. Alternatively, a hypodermic needle may be inserted through the blister (7) at point (12), and then through the thinned region (3) without the need to first remove the vial (1) from the blister (7). To facilitate use of the package in this way the blister (7) may be provided with aligning guides such as dimples (not shown) in its walls to hold the vial (1) steady, and indication of a designated point (12), e.g. by a dimple for  
25       insertion of the needle.

      In an alternative embodiment (not illustrated) the vial (1) may be replaced by a hypodermic syringe barrel made of water vapour permeable plastics materials.

30       In another alternative embodiment (not illustrated) the blister (7) may be replaced by a thin metal foil or metal foil plastics material laminate envelope which is impermeable to atmospheric water vapour.

#### **Experimental Example:**

35       600 mg of a mixture of crystalline sodium amoxycillin and potassium clavulanate, being a 5 : 1 weight ratio of sodium amoxycillin : potassium clavulanate (expressed as the free acid equivalent) was filled into 10ml or 20ml plastic vials made by Daikyo™ from a hydrocarbon polymer called CZ Resin. Such a mixture is suitable for use as an injectable formulation. The vials were divided

into four groups, sealed into a moisture-impermeable aluminium foil laminate pouch with desiccant capsules and stored at controlled temperatures.

**Group:****Contents**

- 5    A                      10ml vials, packed with 1.25g molecular sieve  
       B                      10ml vials, packed with 2.5g molecular sieve  
       C                      10ml vials, no desiccant  
       D                      20ml vials, packed with 1.25g molecular sieve

- 10            Degradation of the vials contents was assessed by measuring the colour of the powder, this having been demonstrated as a very sensitive technique. An increase in the yellow component of the appearance is directly related to generation of degradation products and loss of potency of the active material. Results are set out below:

15

Vials stored at 40°C

Time (months)	A	B	C	D
0	5.1			
1	8.9	8.7	9.7	8.3
9	10.7	11.0	14.1	9.6

Vials stored at 25°C

20

Time (months)	A	C	D
0	5.1		
9	7.8	12.8	8.4

The values quoted are the 'b' value of the L,a,b colour space, a measure of yellowness.

- 25            The initial degradation of all the groups at one month was probably from the small but significant amounts of water in the plastic of the vial, which has to be taken up by the desiccant before drying can start on the vial contents.

Pre-desiccation of the components and careful handling will minimise these losses.

- 30            As can be seen from the accompanying data, the water vapour transmission rate of glass vials with a rubber stopper is very low, while that of the Daikyo™ vials is similar to a typical polyethylene product. Typical water vapour transmission rates are:

5ml glass vials sealed with standard stopper and aluminium seal =  
 0.01mg/day @ 30°/100% R.H.

20ml Daikyo™ vials sealed with standard stopper and aluminium seal =  
0.46mg/day @ 30°/100% R.H.



20ml polyethylene vials sealed with standard stopper and aluminium seal =  
0.40mg/day @ 30°C/100% R.H.

5

**Claims:**

1. A package comprising an inner container (1) suitable for containment of a pharmaceutical formulation (5), the inner container (1) being enclosed within an outer container (7) which is substantially less permeable to water vapour than the inner container (1), the intermediate space between the inner and outer containers containing a desiccant, characterised in that the said inner container is a vial (1) provided with a puncturable seal (3), or a syringe or syringe barrel, suitable for use for transdermal injection of a formulation, and being permeable to water vapour but impermeable to liquid water.
2. A package according to claim 1 characterised in that the inner container is a vial (1) made from pharmaceutically acceptable water vapour-permeable plastics materials, having a puncturable rubber closure (3).
3. A package according to claim 1 characterised in that the inner container is a syringe, or syringe barrel, suitable for use for transdermal injection of a formulation.
4. A package according to any one of claims 1 to 3 characterised in that the water vapour-permeability of the inner container (1) is via a water vapour permeable closure (3) for an opening of the container.
5. A package according to any one of claims 1 to 4 characterised in that the outer container is in the form of a blister pack (7).
6. A package according to claim 5 characterised in that the blister pack (7) has an indication of a designated point (12) for insertion of a hypodermic needle through the blister pack (7) wall and through the puncturable region (3) of a closure for a vial (1) via which water or an aqueous medium may be injected into the vial (1) for dissolution of the contents (5) of the vial and subsequent withdrawal of the so-formed solution.
7. A package according to any one of claims 1 to 4 characterised in that the outer container is in the form of a tray or box closed by a lid, both the tray or box and the lid being made of the packaging material, with a substantially water vapour-impermeable seal formed between the lid and the box or tray, or a metal foil or foil/plastics material laminate envelope.

8. A package according to any one of claims 1 to 7 containing a mixture which comprises potassium clavulanate and sodium amoxycillin.
9. A package according to claim 8 wherein the sodium amoxycillin is in the  
5 form of anhydrous crystalline sodium amoxycillin.
10. A method of storage of a moisture-sensitive pharmaceutical substance, comprising the containment of the substance in the inner container of a package according to any one of claims 1 to 7.



## INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 95/02201

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 B65D77/04 B65D81/26 A61K9/20

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 B65D A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X Y	US,A,2 283 867 (FLOSDORF) 19 May 1942 see page 2, left column, line 18 - right column, line 46; figures ---	1,4,10 2,3,5,7, 8
A	GB,A,1 485 832 (FISONS) 14 September 1977 see the whole document ---	1,7
A	GB,A,2 208 287 (ROUSSEL-UCLAF) 22 March 1989 see page 2, line 32 - page 3, line 2; figure ---	1
Y	EP,A,0 488 323 (TERUMO) 3 June 1992 see page 2, line 30 - page 3, line 34 see page 3, line 55 - page 4, line 41; figures --- -/--	2,5,7

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

## \* Special categories of cited documents :

\*A\* document defining the general state of the art which is not considered to be of particular relevance

\*E\* earlier document but published on or after the international filing date

\*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

\*O\* document referring to an oral disclosure, use, exhibition or other means

\*P\* document published prior to the international filing date but later than the priority date claimed

\*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

\*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

\*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

\*&amp;\* document member of the same patent family

Date of the actual completion of the international search

8 September 1995

Date of mailing of the international search report

27.09.95

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax (+31-70) 340-3016

Authorized officer

Newell, P



## INTERNATIONAL SEARCH REPORT

Inter. Application No.

PCT/EP 95/02201

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	US,A,2 812 231 (ZAR) 5 November 1957 see column 4, line 17 - line 39; figure 6 ---	3
A	EP,A,0 597 097 (HACHIKU) 18 May 1994 see column 20, line 20 - line 49; figures 9-14 ---	6
Y	US,A,4 441 609 (CROWLEY) 10 April 1984 see column 1, line 18 - line 41 see column 2, line 10 - line 42 ---	8
A	EP,A,0 131 147 (BEECHAM) 16 May 1985 cited in the application see page 1, line 7 - line 30 -----	9

# INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 95/02201

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US-A-2283867	19-05-42	NONE	
GB-A-1485832	14-09-77	NONE	
GB-A-2208287	22-03-89	FR-A- 2618762	03-02-89
		AT-B- 393661	25-11-91
		AU-B- 600079	02-08-90
		AU-B- 1092288	23-06-88
		BE-A- 1004986	16-03-93
		CH-A- 674972	15-08-90
		DE-A- 3803772	09-02-89
		DK-B- 169380	17-10-94
		JP-A- 1037375	08-02-89
		LU-A- 87111	03-05-88
		NL-A- 8800279	02-05-88
EP-A-488323	03-06-92	JP-A- 4200465	21-07-92
		AU-B- 642558	21-10-93
		AU-A- 8830591	11-06-92
		US-A- 5217118	08-06-93
US-A-2812231	05-11-57	NONE	
EP-A-597097	18-05-94	WO-A- 9323290	25-11-93
		AU-B- 659160	11-05-95
		AU-B- 1792092	13-12-93
US-A-4441609	10-04-84	AU-B- 525089	21-10-82
		AU-A- 4050678	17-04-80
		BE-A- 870988	03-04-79
		CA-A- 1105385	21-07-81
		CH-A- 642258	13-04-84
		DE-A- 2843318	12-04-79
		FR-A, B 2405711	11-05-79
		GB-A, B 2005538	25-04-79
		JP-C- 1494273	20-04-89
		JP-A- 54076831	19-06-79
		JP-B- 63041886	19-08-88
		NL-A, B 7810176	17-04-79
		SE-B- 435899	29-10-84

# INTERNATIONAL SEARCH REPORT

International Application No.

PCT/EP 95/02201

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US-A-4441609		SE-A- 7810591	11-04-79
		SE-B- 451668	26-10-87
		SE-A- 8107592	17-12-81
		US-A- 4301149	17-11-81
<hr/>			
EP-A-131147	16-01-85	AU-B- 2924284	13-12-84
		DE-A- 3474023	20-10-88
		JP-B- 7020971	08-03-95
		JP-A- 60008295	17-01-85
<hr/>			